Question.2715 - Economic Analysis of Supply and Market Structure of Healthcare Industry The chosen industry: Pharmaceutical (patented drug)
Answer Below:
Delivering xxxxxxxxxx Patient-Centric xxxxxxxxxx A xxxxx on xxxxxxxx Drugs xx the xxxxxxxxxxxxxx Industry xx the xxxxxxxx of xxx Health xxxxxxx Manager xx the xxxx the xxxxxxx deals xxxxxx of xxxxxxxx drugs xx patients xxxxx are xxxxxxxx medicines xxxxx are xxxxx drugs xxxxxxxx through xxxxxxxxxxx research xxx experiments xxxxxxx with xx addition xx huge xxxxxxxxxxx in xxxxxxxxxx research xxxxxxxx trials xxx regulatory xxxxxxxxx Gurgula xxx products xxxxxxxx by xxx company xxxx effectiveness xx treating xxxxxxx diseases xxx in xxxxxxxxx the xxxxxx conditions xx patients xxxxx patented xxxxx typically xxxxx several xxxxxxxxxx over xxxxxxx alternatives xxxxxxxxx Efficacy xxx Safety xxxxxxxx drugs xxx subjected xx severe xxxxxxxx testing xxxxxxxxx to xxxxxxx both xxxxxxxx and xxxx usage xxxxxxxxxx These xxxxxxxxxxx are xxxxxxxx to xxxxxxxxxxxxxxx target xxxxxxxx disease-causing xxxxxxxx or xxxxxxxxxx targets xxxxxxx avoiding xxx untargeted xxxxxxx of xxxxx drugs xxx non-specific xxxxxxxxxxxxxx substitutes xxxxxxx Assurance xxxxxxxxxxxxxx companies xxx vigilant xxx invest xx good xxxxxxx assurance xxxxxxxx to xxxxxx competitive xx a xxxxxx characterized xx more xxxxxx products xxx generic xxxxxxxxxxxx This xx a xxxxxxxxx of xxxxxxx which xx required xx prevent xxxxxxxxxxxx product xxxxxxxxx and xxxx user xxxxxxxxxxx Market xxxxxxxxx Analysis xxxxxxxxxxxxxx Industry xxx pharmaceutical xxxxxx works xxxxx an xxxxxxxxxxxxx market xxxxxxxxx which xx characterized xx a xxx dominant xxxxxxx that xxx capable xx making xxxxxxxxxxx market xxxxxxxxx This xxxxxx structure xx primarily xxxxxxxxxx to xxxxxxx key xxxxxxxxxxxxxxx of xxx pharmaceutical xxxxxxxx High xxxxxxxx to xxxxx Because xx its xxxxxxxxxxxxxxxxx and xxxx regulated xxxxxx the xxxxxxxxxxxxxx industry xxx substantial xxxxxxxxx to xxxxxxxx to xx profitable xx commercialize xxx launch xxx patented xxx drug xx the xxxxxx requires xxxxxx of xxxxxxxx and xxxx a xxxxxxx layer xx approval xxxxxxxxxx both xx legal xxxxxxxxxxx and xxxxxxxxxx bodies xxxxxxx al xxxxx barriers xxxxxxxxxx newcomers xxx therefore xxxxxxx factor xxxx contributes xx the xxxxxxxxxxxxx of xxx large xxxxxx companies xx the xxxxxxxx Product xxxxxxxxxxxxxxx The xxxxx of xxx patented xxxxx in xxx pharmaceutical xxxx pharmaceutical xxxxxxxxxxxxxxx in xxxxx of xxxxxxxxxxx effectiveness xxxxxx profiles xxx intellectual xxxxxxxx protection xxxxxxxx al xxxx patents xxxxx to xxx one-of-a-kind xxxxxxx lines xxxx specific xxxxxxxx benefits xxxx give xxxxxxxxxxxxxx companies x pricing xxxxx and xxxxxxx to xxxxxxx based xx product xxxxxxxxxx not xxxxx Research xxx Development xxxxx Pharmaceutical xxxxx bear xxxxxxxxxxxx expenditures xxxx include xxxxxxxx development xxx finally xxxxxxxx a xxx drug xxxx the xxxxxx These xxxxx cover xxx prices xxxx for xxxxxxxxxx research xxxxxxxx trials xxx conformity xxxxx Thus xxxxxxxxxxxxxx companies xxxx to xxxxxxx these xxxxx and xxxxxx profits xx be xxxxxxxxxx and xxxx are xx example xx an xxxxxxxxxxxxx industry xxxxxxxxxxx Pricing xxxxxxxxxx for xxxxxxxx Drugs xx an xxxxxxxxxxxxx Pharmaceutical xxxxxx In xxx pharmaceutical xxxxxxxxxx prices xxx patented xxxxx are xxxxxxxxxx through x combination xx things xxxxxxxx by xxx oligopolistic xxxxxx structure xx a xxxxxx Service xxxxxxx within xxxx industry xxx company xxxxxxxx patented xxxxx designed xx deal xxxx precise xxxxxxxxxx situations xxx pricing xx these xxxxxxxx is xxxxxxxxxx through xxxxxxx considerations xxxxxxxx and xxxxxxxxxxx Costs xxx prices xx patented xxxxx reflect xxx full-size xxxxxxxxxxx in xxxxxxx and xxxxxxxxxxx required xx discover xxxxxx and xxxxxx those xxxxxxxxxxx to xxx market xxxxxxxxxxxxxx businesses xxx looking xx recoup xxxxx costs xxxx the xxxxxx s xxxxxxxx Market xxxxxx and xxxxxxxxxxx Dynamics xxxxxxx selections xxx motivated xx marketplace xxxxx for xxx drug xxx aggressive xxxxxxxx in xxx enterprise xxxxxxxxx and xxxxxxxx Pharmaceutical xxxxxxxxxx may xxxxxxx marketplace xxxxxxxx to xxxxxx demand xxxxxxxxxx and xxxxxxxxxx pricing xxxxxxxxxx Impact xx Private xxx Public xxxxxxxxx on xxxxxxx for xxxxxxxx Drugs xx the xxxxxxxxxxxxxx industry xxx return xx revenue xxxxxxx from xxx supply xx patented xxxxx is xxxxxxxx strongly xx the xxxxxxxxxxxx of xxxx privately xxx publicly xxxxxx insurance xxxxxxx Private xxxxxxxxx payment xxxxxx allow xxxxxxxx to xxx these xxxxxxxxxxx with xxx payment xx deductibles xxxxx public xxxxxxxxx programs xxxx as xxxxxxxx and xxxxxxxx cover xxxxxxxx individuals xx negotiable xxxxx PARASRAMPURIAet xx The xxxxxxx is xxxx the xxxx private xxxxxxxxx exists xxx more xxxxxxxx can xxxxxx patented xxxxx therefore xxxxxxxxxx the xxxxx Additionally xxxxxx program xxxxxxxx can xxxxxxx a xxxxxx source xx revenue xxxxxxx agreed xxxxxxxxxxxxx rates xxxxxxxx generally xx lower xxxxxxx compared xx those xx privately xxxxxxxxxx payments xxxxxxxxxx Regulation xxxxxxxxx the xxxxxxxxxxxxxx Industry xx is xxxxxxxxx to xxxxxxxxx the xxxxxxxxxx regulation xxxxx predominantly xxxxxxx the xxxxxxxxxxxxxx industry xx terms xx the xxxxxxx or xxx service xxxxxxxx to xxx patients xxxxx is xxx Drug xxxxx Competition xxx Patent xxxx Restoration xxx known xx the xxxxxx Waxman xxx Haltermann xxxxxxx in xxxxxx the xxxxxx States xxx its xxxx purpose xxx the xxxxxxxxx of xxxxxxxxxx for xxxxxxxxxxxxxx innovation xx promote xxxxxxxxxxx and xxxxxxxxxxxxx in xxx market xxx Abbreviated xxx Drug xxxxxxxxxxx ANDA xxxxx was xxxxxxxxxx by xxx Hatch- xxxxxx Act xxxxx expedited xxx approval xx generic xxxxx by xxxxxxxxxxxxx bioequivalence xxxx a xxxxx name xxxx already xxxxxxxx by xxx FDA xxxxxxx al xxxx regulation xxxxx many xxxxx that xxx patented xx supply xx providing x generic xxxxxxxxxx to xxxxx the xxxxxx after xxx expiration xx patent xxxxxxxxxxx which xx turn xxxxxxxx price xxxxxxxxxxx and xxxxxxxxx the xxxxxxxxxxxxx of xxxxxxxxxxx for xxxxxxxx Addressing xxxxxx Failures xxxx Government xxxxxxxxxx The xxxxxxxxxxxxxxxxxxxx referred xx as xxx Hatch-Waxman xxx was xxxxxxxxxxx to xxxx with xxxxxxx market xxxxxxxx in xxx pharmaceutical xxxxxxxx One xxx market xxxxxxx that xxxx law xxxxxxxxx to xxxxxxxx is xxx difficulty xx monopolistic xxxxxxx power xxxx through xxxxxxxxxxxxxx businesses xxx to xxxxxx exclusivity xxxxxxx Patented xxxxx frequently xxxx direct xxxxxxxxxxx allowing xxxxxx to xxx high xxxxxx that xxx restrict xxxxxxxx person xxxxxx and xxxxxxxxxxxxx This xxxxxxxxxxxx conduct xxx bring xxxxx inefficiencies xx expenses xxxxx not xxxxxxxxx the xxxxxxxxx cost xx production xxx innovation xxxxxxxxxxxx the xxxxxxxxxxxx Act xxxxx to xxxxxxx the xxxxxx failure xxxxxxxxxx with xxxxxxx asymmetry xxxxxxxxxxxxxxx and xxxxxxx drug xxxxxxxxxxxxx Morganet xx Prior xx this xxxxxxxxxx everyday xxxxxxxxxxxxx faced xxxxxxxxxxx obstacles xx getting xxxx the xxxxxxxxxxx due xx the xxxxxxxxx and xxxxxxxxxxx method xx duplicating xxxxxxxx trials xxx obtaining xxxxxxxxxx approval xx a xxx result xxxxxxxxxxx pharmaceutical xxxxxxxxx may xxxx to xxxx marketplace xxxxxxxxxxx for xxxxxxxxx intervals xxxxxxxxx charge xxxxxxxxxx and xxxxxxxxxx References xxxxx R xxxxxxxx C xxx Lasio x Collusion xx the xx generic xxxx industry xxxxxxxxxxxxx Journal xx Industrial xxxxxxxxxxxx p xxxxx academic xxx com xxx article- xxx doi xxx lsaa xxxx pdf xxxxxx J x Avorn x and xxxxxxxxxx A x FDA xxxxxxxx and xxxxxxxxxx of xxxxxxxxxxxxxxx - xxxx pp x http xxxxx s xxxxxxxxx com xx fac xxx cd xxxx abcd x b xxxxxxxxxxx andRegulationofPharmaceuticals xxx Gurgula x Strategic xxxxxxxxx by xxxxxxxxxxxxxx companies xxxxxx competition xxx intervene xxxxxxxxxxxxxxxxx Review xx Intellectual xxxxxxxx and xxxxxxxxxxx Law xx - xxxxx link xxxxxxxx com xxxxxxx s x - x Haltermann x J xxx High xxxx of xxxxxxxxxxxxxx Acquisitions xxxxxxxxxx Social xxxxxxx or xxxxxxxxxx Inequality xxxxx Dame x on xxxxxxxx Tech x https xxxx harvard xxx bitstream xxxxxx FOWLER-DISSERTATION- xxx sequence xxxxxx S x Bathula x S xxx Moon x Pricing xx pharmaceuticals xx becoming x major xxxxxxxxx for xxxxxx systems xxx https xxxx springer xxx article x - x - xxxxxxxxx L x and xxxxxxxx H xxxxxxxxx the xxxxxx system xxxxxx Proposal xxxxx law xxxxxxxx edu xxx content xxxxxxx Ouellette xxxxxxxx LO xxxxx pdf xxxxxxxxxxxxx S xxxxxxxx A xxxx A xxx BERGER x COST xx GENERIC xxxx DEVELOPMENT xxx APPROVAL xxxxx http xxxx hhs xxx sites xxxxxxx files xxxxxxxxx e x b x c x cc x cost-of-generic-drugs-erg xxx Singh x Singh x Kumar x Kulkarni x T xxx Thakkar x R xxxxxx of xxxxxxx drug xxxx fee xxx and xxxxx initiatives xx generic xxxx approval xxxxxxx in xxx USA xxxxx Journal xx Pharmaceutical xxxxxxxx and xxxxxx Care x https xxx tandfonline xxx doi xxxMore Articles From Management
.ico)
.ico)
.ico)
.ico)
